Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab maintenance with or without involved-field TOMO radiotherapy in stage III follicular lymphoma in complete remission
ChiCTR2000032550Phase 3Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 5-year disease-free survival. Started May 2012; status: recruiting.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2000032550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032550.